Literature DB >> 22571484

Comparison of cytochrome P450 2C subfamily members in terms of drug oxidation rates and substrate inhibition.

Toshiro Niwa1, Hiroshi Yamazaki.   

Abstract

This review focuses on identification of important active-site residues of the cytochrome P450 2C (CYP2C) subfamily in terms of substrate specificity. A meta-analysis was performed on the reported literature regarding (1) values of the Michaelis-Menten constant (K(m)), maximal velocity (V(max)), and intrinsic clearance (V(max)/K(m)) for 74 metabolic reactions of 45 substrates mediated by human CYP2C8, CYP2C9, CYP2C18, and CYP2C19 and (2) inhibition constants (K(i)) for 3 inhibitors. Although the kinetic behaviors of these CYP2C subfamily members depend on the metabolic reaction, the ratios of V(max)/K(m) values for CYP2C19/CYP2C9 and CYP2C8/CYP2C19, but not for CYP2C8/CYP2C9, were more closely correlated with K(m) values than with V(max) values, suggesting that, for many metabolic reactions, differences in affinity may be more important than differences in capacity for the substrate/reaction specificity of the CYP2C subfamily, especially for CYP2C19. In addition, it has been proposed that the residues involved in substrate recognition sites (SRS) 1, SRS 3, and/or SRS 4 are important for the metabolizing capacity and/or the substrate binding of CYP2C9 and CYP2C19. In contrast to the reasonable amount of kinetic data available, there are few reports comparing the effects of inhibitors [inhibitory constant (K(i)) or 50% inhibitory concentration (IC(50))] on metabolic reactions mediated by the CYP2C subfamily. Collectively, these findings provide insights into the contributions of CYP2C subfamily members to drug metabolism and adverse drug interactions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22571484     DOI: 10.2174/138920012802850092

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  4 in total

Review 1.  Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes.

Authors:  Hannu Raunio; Mira Kuusisto; Risto O Juvonen; Olli T Pentikäinen
Journal:  Front Pharmacol       Date:  2015-06-12       Impact factor: 5.810

2.  Noncompetitive inhibition of human CYP2C9 in vitro by a commercial Rhodiola rosea product.

Authors:  Ole Kristian Forstrønen Thu; Olav Spigset; Bent Hellum
Journal:  Pharmacol Res Perspect       Date:  2017-08

3.  In Vitro Inhibitory Effects of Synthetic Cannabinoid EAM-2201 on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.

Authors:  Tae Yeon Kong; Soon-Sang Kwon; Jae Chul Cheong; Hee Seung Kim; Jin Young Kim; Hye Suk Lee
Journal:  Molecules       Date:  2018-04-16       Impact factor: 4.411

4.  Influence of Selected Carbon Nanostructures on the CYP2C9 Enzyme of the P450 Cytochrome.

Authors:  Justyna Sekretarska; Jarosław Szczepaniak; Malwina Sosnowska; Marta Grodzik; Marta Kutwin; Mateusz Wierzbicki; Sławomir Jaworski; Jaśmina Bałaban; Karolina Daniluk; Ewa Sawosz; André Chwalibog; Barbara Strojny
Journal:  Materials (Basel)       Date:  2019-12-11       Impact factor: 3.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.